The use of paclitaxel in the management of early stage breast cancer
Griffin S, Dunn G, Palmer S, Macfarlane K, Brent S, Dyker A, Erhorn S, Humphries C, White S, Horsley W, Ferrie L, Thomas S
Record ID 32011001404
English
Authors' recommendations:
The submission did not include a systematic review for clinical or cost-effectiveness evidence. As a result, potentially relevant trials and previously published studies were omitted. The main comparator used did not represent standard care in the UK NHS and a large number of relevant comparators were omitted, including docetaxel, another taxane, as licensed for the same indication. The manufacturer did not consider potentially important patient subgroups defined by baseline risk, and the cost-effectiveness result in the average overall patient population may conceal important variation between subgroups.
Overall, although the economic model may have indicated that the addition of four cycles of paclitaxel to four cycles of AC may be cost-effective compared with providing four cycles of AC only, this comparison is not informative to current clinical practice in the UK NHS. In the context of this review it is not possible for the ERG to predict the cost-effectiveness of paclitaxel compared with more appropriate, and potentially more effective, relevant comparators such as six cycles of FAC or the licensed indication of docetaxel. It is therefore impossible for the ERG to predict what effect including these comparators would have on the cost-effectiveness of paclitaxel for adjuvant treatment of early breast cancer.
Details
Project Status:
Completed
Year Published:
2009
URL for published report:
http://www.hta.ac.uk/1543
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Clinical Trials as Topic
- Cost-Benefit Analysis
- Technology Assessment, Biomedical
- Antineoplastic Combined Chemotherapy Protocols
- Breast Neoplasms
- Cyclophosphamide
- Doxorubicin
- Paclitaxel
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
<p>2009 Queen's Printer and Controller of HMSO</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.